



ABN 53 075 582 740

ASX ANNOUNCEMENT
4 July 2016

Director Retirement and Informal Board-Shareholder Meetings

Bionomics Limited (ASX:BNO; OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, today announced that Dr Alan W. Dunton would retire from its Board of Directors.

Graeme Kaufman, Chairman of Bionomics said, "Alan has made a significant contribution to Bionomics, and the Board and Management team are very appreciative of his time and efforts. Subsequent to his appointment to Bionomics' Board, Alan joined Purdue Pharma as Senior Vice President, Research and Development, and it has become apparent in recent months that it will be challenging to dedicate the appropriate amount of time to Bionomics while maintaining this senior executive role. While we are disappointed that Alan will no longer be involved with Bionomics, we understand and respect his decision."

Given the recent appointments of David Wilson and Peter Turner as Non-Executive Directors, the Board believes Bionomics has a strong governance structure, with the requisite composition, skills and commitment from directors. Following Dr Dunton's retirement, the Board will consist of six members.

Separately, Bionomics will hold two Board-shareholder meetings (one each in Adelaide and Sydney) following its FY 2016 result in August. The meetings will provide an informal forum for investors to interact with Bionomics' Directors, and to meet Mr Turner and Mr Wilson.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Australia
Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US
Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that

is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.